|Phenotype / cell stem origin
|| This leukemia is thought to derive from the transformation of a multipotent myeloid progenitor cell. In the adult patient multilineage dysplasia is a common finding and in some cases a minority of myeloid blast cells is present.|
The blast cells show one or more megakaryocytic markers (i.e. Factor VIII, CD61, CD41, or CD42), they test negative when using the anti-myeloperoxidase monoclonal antibody and never show coordinated expression of lymphoid markers, though isolated CD2 or CD7 positivity can be found on some occasions. The CD34, CD13 and CD33 markers are positive in a substantial fraction of cases, as is the case with the CD36/thrombospondin receptor.
The myeloperoxidase stain is negative by light microscopy, but ultrastructural peroxidase activity with a specific peri-nuclear staining pattern can be detected at the electron microscopy level.
|Epidemiology|| The disease is rare and, due to difficulty in diagnosis, its exact incidence is not known. Reasonably, it may account for approximately 1-2% of all de novo acute myeloid leukemias (AML) in the adult population, but the incidence in the pediatric age group is higher, partly due to an association with Down syndrome.|
|Clinics|| The presentation is usually acute, though AMegL may develop after myelodysplastic syndrome or chronic myelogenous leukemia (CML).|
In some cases acute myelofibrosis is the presentation picture.
AMegL should be distinguished from AML with megakaryoblastic involvement showing a minority of megakaryoblasts.
In children there is an association with Down syndrome.
|Cytology|| The blast cell morphology varies from case to case. In some patients the blasts are undifferentiated and the diagnosis requires immunophenotyping or electron microscopy studies. Dysmegakaryocytopoiesis is rather frequent. Other patients may show bleb-forming blasts, but this feature is nor specific for megakaryoblasts. Micromegakaryocytes can be frequently seen.|
|Pathology|| The bone biopsy almost invariably shows fibrosis, which can be extensive in up to 75% of the cases.|
Spleen enlargement is frequently seen in children, less frequently in adults.
|Treatment|| Myeloablative treatment followed, whenever possible, by allogeneic or autologous bone marrow transplant is the treatment of choice|
|Prognosis|| In general, the prognosis is severe. 30-to-50 % of the adult patients achieve a complete morphologic remission, but the majority relapse within a few months. Median duration of CR and survival in a study was 10.6 months and 10.4 months, respectively. Some children may fare better, with a 50% 3-year event free survival in AML-M7 post Down Syndrome or with the t(1;22) (see below). Prognosis is dismal in children with other cytogenetic abnormalities.|
| Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization.|
| Alvarez S, MacGrogan D, Calasanz MJ, Nimer SD, Jhanwar SC|
| Genes, chromosomes & cancer. 2001 ; 32 (3) : 285-293.|
| Megakaryoblastic acute leukemia: identification by the ultrastructural demonstration of platelet peroxidase.|
| Breton-Gorius J, Reyes F, Duhamel G, Najman A, Gorin NC|
| Blood. 1978 ; 51 (1) : 45-60.|
| Multipotent stem cell involvement in megakaryoblastic leukemia: cytologic and cytogenetic evidence in 15 patients.|
| Cuneo A, Mecucci C, Kerim S, Vandenberghe E, Dal Cin P, Van Orshoven A, Rodhain J, Bosly A, Michaux JL, Martiat P|
| Blood. 1989 ; 74 (5) : 1781-1790.|
| Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH).|
| Dastugue N, Lafage-Pochitaloff M, Pagès MP, Radford I, Bastard C, Talmant P, Mozziconacci MJ, Léonard C, Bilhou-Nabéra C, Cabrol C, Capodano AM, Cornillet-Lefebvre P, Lessard M, Mugneret F, Pérot C, Taviaux S, Fenneteaux O, Duchayne E, Groupe Français d'Hematologie Cellulaire, Berger R|
| Blood. 2002 ; 100 (2) : 618-626.|
| Acute megakaryoblastic leukaemia: a national clinical and biological study of 53 adult and childhood cases by the Groupe Français d'Hématologie Cellulaire (GFHC).|
| Duchayne E, Fenneteau O, Pages MP, Sainty D, Arnoulet C, Dastugue N, Garand R, Groupe Français d'Hématologie Cellulaire, Groupe Français de Cytogénétique Hématologique (GFCH)., Flandrin G|
| Leukemia & lymphoma. 2003 ; 44 (1) : 49-58.|
| Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia.|
| Ma Z, Morris SW, Valentine V, Li M, Herbrick JA, Cui X, Bouman D, Li Y, Mehta PK, Nizetic D, Kaneko Y, Chan GC, Chan LC, Squire J, Scherer SW, Hitzler JK|
| Nature genetics. 2001 ; 28 (3) : 220-221.|
| Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia.|
| Mercher T, Coniat MB, Monni R, Mauchauffe M, Nguyen Khac F, Gressin L, Mugneret F, Leblanc T, Dastugue N, Berger R, Bernard OA|
| Proceedings of the National Academy of Sciences of the United States of America. 2001 ; 98 (10) : 5776-5779.|
| Chromosome 19 abnormalities are commonly seen in AML, M7.|
| Nimer SD, MacGrogan D, Jhanwar S, Alvarez S|
| Blood. 2002 ; 100 (10) : 3838-3839.|
| Leukemias with megakaryoblastic involvement: clinical, hematologic, and immunologic characteristics.|
| San Miguel JF, Gonzalez M, Cañizo MC, Ojeda E, Orfao A, Caballero MD, Moro MJ, Fisac P, Lopez Borrasca A|
| Blood. 1988 ; 72 (2) : 402-407.|
| Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience.|
| Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH, Dewald G, Cassileth PA, Oken MM, Rowe JM|
| Blood. 2000 ; 96 (7) : 2405-2411.|
| Megakaryoblastic leukemia and Down's syndrome: a review.|
| Zipursky A, Peeters M, Poon A|
| Pediatric hematology and oncology. 1987 ; 4 (3) : 211-230.|